Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aleksander Krag

Showing results (71-80 of 325) with videos related to

Pageof 33
Sort By:
Lancet (London, England)|November 2, 2024
Steatotic liver diseaseMads Israelsen, Sven Francque, Emmanuel A Tsochatzis, et al.
The Lancet. Gastroenterology & Hepatology|July 18, 2025
Screening for advanced steatotic liver diseaseStine Johansen, Fredrik Åberg, Emmanuel A Tsochatzis, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 18, 2010
Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retentionAleksander Krag, Erling B Pedersen, Søren Møller, et al.
Journal of Hepatology|December 17, 2011
Betablockers induce cardiac chronotropic incompetenceAleksander Krag, Søren Møller, Andrew K Burroughs, et al.
The Lancet. Gastroenterology & Hepatology|January 24, 2025
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALDAleksander Krag, Nikolaj Torp, Zobair M Younossi, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|March 27, 2016
ReplyLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Ugeskrift for Laeger|July 9, 2019
[Statins are safe in patients with liver diseases and may have a beneficial effect]Mie Balle Hugger, Mads Israelsen, Camilla Dalby Hansen, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2011
Effects of treatment with β-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosisChristine Winkler, Lise Hobolth, Aleksander Krag, et al.
Journal of Hepatology|May 18, 2024
A turning point in hepatology? EASL reflects on the first approved drug for MASHSven Francque, Aleksander Krag, Debbie L Shawcross, et al.
Pageof 33

Showing results (71-80 of 325) with videos related to

Sort By:
Pageof 33
Lancet (London, England)|November 2, 2024
Steatotic liver diseaseMads Israelsen, Sven Francque, Emmanuel A Tsochatzis, et al.
The Lancet. Gastroenterology & Hepatology|July 18, 2025
Screening for advanced steatotic liver diseaseStine Johansen, Fredrik Åberg, Emmanuel A Tsochatzis, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|November 18, 2010
Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retentionAleksander Krag, Erling B Pedersen, Søren Møller, et al.
Journal of Hepatology|December 17, 2011
Betablockers induce cardiac chronotropic incompetenceAleksander Krag, Søren Møller, Andrew K Burroughs, et al.
The Lancet. Gastroenterology & Hepatology|January 24, 2025
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALDAleksander Krag, Nikolaj Torp, Zobair M Younossi, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patientsLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Hepatology (Baltimore, Md.)|March 27, 2016
ReplyLars Bossen, Aleksander Krag, Hendrik Vilstrup, et al.
Ugeskrift for Laeger|July 9, 2019
[Statins are safe in patients with liver diseases and may have a beneficial effect]Mie Balle Hugger, Mads Israelsen, Camilla Dalby Hansen, et al.
European Journal of Gastroenterology & Hepatology|March 15, 2011
Effects of treatment with β-blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosisChristine Winkler, Lise Hobolth, Aleksander Krag, et al.
Journal of Hepatology|May 18, 2024
A turning point in hepatology? EASL reflects on the first approved drug for MASHSven Francque, Aleksander Krag, Debbie L Shawcross, et al.
Pageof 33